A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients

Haemophilia

Volumn 17, Issue 3, 2011, Pages 516-521

  Teitel, J ^a   Berntorp, E ^b   Dolan, G ^c   Fischer, K ^d   Gringeri, A ^e   Kessler, C ^f   Lambert, T ^g   Leissinger, C ^h   Nemes, L ⁱ   Shima, M ^j  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b LUND UNIVERSITY   (Sweden)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF MILAN   (Italy)

^f GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^g BICÊTRE HOSPITAL   (France)

^h TULANE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ State Health Center   (Hungary)

^j NARA MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

Activated prothrombin complex concentrate; Activated recombinant factor VII; Bypassing therapy; Haemophilia; Inhibitors; Prophylaxis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; BLOOD CLOTTING INHIBITOR BYPASSING AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; BYPASSING AGENT PROPHYLAXIS; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; HEMOPHILIA A; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; STANDARDIZATION;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; HEMOPHILIA A; HEMORRHAGE; HUMANS;

EID: 79955154649     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02440.x     Document Type: Article

References (35)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
2. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
3. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
4. Antunes SV, Vicari P, Cavalheiro S, Bordin JO. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia 2003; 9: 573-7.
5. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
6. Steen Carlsson K, Hojgard S, Glomstein A et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555-66.
7. Buchanan GR, Kevy SV. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies. Pediatrics 1978; 62: 767-74.
8. Penner JA, Kelly PE. Management of patients with factor vIII or IX inhibitors. Semin Thromb Hemost 1975; 1.
9. Kelly P, Penner JA. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. JAMA 1977; 236: 2061-4.
10. Yolken RH, Hilgartner MW. Prothrombin complex concentrates. Use in treatment of hemophiliacs with factor VIII inhibitors. Am J Dis Child 1978; 132: 291-3.
11. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
12. Schramm W, Royal S, Kroner B et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
13. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years''Bonn protocol'. Vox Sang 1996; 70(Suppl. 1): 30-5.
14. Kreuz W, Escuriola-Ettingshausen C, Mentzer D. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors [abstract]. Blood 2000; 96: 266a. Abstract 1141.
15. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261-8.
16. Schino L, Mancuso G, Morfini M, Piseddu G, Sbrighi P. APCC (FEIBA) home therapy retrospective survey in long-term secondary prophylaxis on 4 hemophilia A patients with factor VIII inhibitor. Poster presented at the XXVII International Congress fo the World Federation of Hemophilia; May 21-25, 2006; Vancouver, Canada.
17. DiMichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
18. Cheng S-N, Chen Y-C, Chiag J-L. FEIBA prophylaxis in hemophilia A patient with inhibitors decrease bleeding episodes, maintain arthropathy and enhance quality of life. Haemophilia 2006; 12. Abstract 14 PO 371.
19. Ewing N, DeGuzman C, Pullens L. Anamnesis in patients with hemophilia and inhibitors who receive activated prothrombin complex concentrates for prophylaxis. J Thromb Haemost 2007; 5. Abstract number P-T-158.
20. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 2007; 13: 249-55.
21. Lambert T, Rothschild C, Goudemand J et al. Secondary prophylaxis with activated prothrombin complex concentrates (APCC) reduces bleeding frequency in haemophilia a patients with inhibitors. J Thromb Haemost 2009; 7. Abstract PP-TH-593.
22. Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia 2009; 15: 733-42.
23. Jimenez-Yuste V, Alvarez MT, Martin-Salces M et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia 2009; 15: 203-9.
24. Escuriola Ettingshausen C, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction. A prospective clinical case series. Haemophilia 2009; 16: 90-100. DOI.
25. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
26. Morfini M, Auerswald G, Kobelt RA et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-7.
27. Leissinger C, Negrier C, Berntorp E et al. A prospective, randomized, crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data. Poster presented at the Hemophilia World Congress 2010; World Federation of Hemophilia; July 10-14, 2010; Buenos Aires, Argentina.
28. Berntorp E, Astermark J, Bjorkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9(Suppl. 1): 1-4.
29. Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia 2004; 10: 147-57.
30. Centers for Disease Control and Prevention. The Universal Data Collection Program. July 2006/Vol 8/No.1. Available at.
31. Leissinger C, Négrier C, Berntorp E et al. A prospective, randomized, crossover study of an activated prothrombin complex concentrate for secondary prophylaxs in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data. Poster presented at the 29th World Federation of Hematology Congress; July 10-14, 2010; Buenos Aires, Argentina.
32. Gomperts ED, Astermark J, Gringeri A, Teitel J. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors. Blood Rev 2008; 22(Suppl. 1): S1-11.
33. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
34. Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77(Suppl. 1): 25-7.
35. van den Berg HM, Dunn A, Fischer K, Blanchette VS. Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy. Haemophilia 2006; 12(Suppl. 3): 159-68.